| __timestamp | Incyte Corporation | Pfizer Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 165772000 | 14097000000 |
| Thursday, January 1, 2015 | 196614000 | 14809000000 |
| Friday, January 1, 2016 | 303251000 | 14837000000 |
| Sunday, January 1, 2017 | 366406000 | 14784000000 |
| Monday, January 1, 2018 | 434407000 | 14455000000 |
| Tuesday, January 1, 2019 | 468711000 | 14350000000 |
| Wednesday, January 1, 2020 | 516922000 | 11615000000 |
| Friday, January 1, 2021 | 739560000 | 12703000000 |
| Saturday, January 1, 2022 | 1002140000 | 13677000000 |
| Sunday, January 1, 2023 | 1161300000 | 14771000000 |
| Monday, January 1, 2024 | 1242157000 | 14730000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, effective cost management is crucial. This analysis of Selling, General, and Administrative (SG&A) expenses from 2014 to 2023 offers a glimpse into the financial strategies of Pfizer Inc. and Incyte Corporation. Over this period, Pfizer's SG&A expenses have shown a steady pattern, peaking in 2016 and 2023, with a slight dip in 2020, reflecting a strategic response to market dynamics. In contrast, Incyte Corporation's expenses have surged by over 600%, highlighting its aggressive expansion and investment in growth. By 2023, Incyte's SG&A expenses reached nearly 12% of Pfizer's, up from just 1% in 2014. This stark contrast underscores the differing approaches of a pharmaceutical giant and a rising star, offering valuable insights into their operational priorities and market positioning.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Incyte Corporation
Pfizer Inc. and Viatris Inc.: SG&A Spending Patterns Compared
Pfizer Inc. and Sarepta Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Walgreens Boots Alliance, Inc.
Comparing SG&A Expenses: Pfizer Inc. vs Cytokinetics, Incorporated Trends and Insights
Operational Costs Compared: SG&A Analysis of Pfizer Inc. and Vericel Corporation
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Incyte Corporation
BeiGene, Ltd. or Incyte Corporation: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Incyte Corporation and Ascendis Pharma A/S
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Jazz Pharmaceuticals plc
Cost Management Insights: SG&A Expenses for Incyte Corporation and Corcept Therapeutics Incorporated